ARTICLE | Finance
Deal driver
BeiGene’s $750M offering could jump-start Chinese bellwether’s in-licensing plans
January 19, 2018 11:15 PM UTC
A $750 million offering from BeiGene Ltd. (NASDAQ:BGNE) should give the Chinese biotech enough financial firepower to accelerate its new in-licensing strategy and position itself as a partner of choice for innovative cancer therapies.
BeiGene raised its follow-on on Jan. 18 through the sale of 7.4 million ADSs at $101. Goldman Sachs, Morgan Stanley, Cowen, Leerink Partners and William Blair underwrote the deal. ...